Browsing by Author "Başkan, Emel Bülbül"
Now showing 1 - 20 of 80
- Results Per Page
- Sort Options
Publication A case of mycosis fungoides-like lesions developing after levetiracetam therapy(Elsevier Science Inc, 2014-01-01) Bora, İbrahim; BORA, İBRAHİM HAKKI; BİCAN DEMİR, AYLİN; Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Demir, Aylin Bican; Balaban, Şaduman; BALABAN ADIM, ŞADUMAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0001-6739-8605; V-7170-2017; JCE-6657-2023; AAH-1388-2021Levetiracetam is a relatively new antiepileptic drug that has previously not been associated with severe dermatological side effects. We report the case of a 31-year-old male treated with levetiracetam for seizures who subsequently developed a mycosis fungoides-like drug reaction that resolved upon dosage reduction. (C) 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.Item Acquired bilateral nevoid telangiectasia syndrome with gastrointestinal involvement(John Libbey Eurotext, 2011) Turan, Hakan; Turan, Aysegul; Sarıcaoğlu, Hayriye; Başkan, Emel Bülbül; Keskin, Murat; Adım, Saduman Balaban; Tunalı, Şükran; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 14055302400; 6603722836; 6602518817; 23050640000; 14046617400; 7004191748Item Acroangiodermatitis in a below-knee amputation stump(Wiley, 2011-07) Turan, Hakan; Başkan, Emel Bülbül; Adım, Şaduman Balaban; Sarıcaoğlu, Hayriye; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6602518817; 15730076300; 6603722836Item Analysis of p53 gene mutations in parapsoriasis(Wiley, 2006) Başkan, Emel Bülbül; Tunca, Berrin; Çeçener, Gülşah; Tunalı, S.; Egeli, Ünal; Sarıcaoğlu, H.; Adım, Şadıman Balaban; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; 0000-0001-7904-883X; 0000-0002-1619-6680; AAH-1388-2021; AAH-1420-2021; ABI-6078-2020; 6602518817; 9280090300; 49762870600; 7004191748; 49762749200; 6603722836; 49762661900The histological diagnosis of the initial stages of Mycosis Fungoides (MF) have not yet been established by exact morphological criteria.1 The borderline between parapsoriasis and MF is not clear due to non-specific changes in the early stages of MF. The underlying molecular changes which may occur during progression or transition from parapsoriasis and early MF to advanced stages have not yet been clarified either.2 However, abnormalities of cell cycle control genes and well-defined tumour suppressor genes may contribute to the disease pathogenesis and progression. The p53 gene plays an important role in the control of cell death and proliferation, inducing cell cycle arrest and/ or apoptosis in response to various cellular stress, and alterations of the p53 gene are commonly associated with malignant transformation.3 The p53 gene mutations, one of the most common genetic alterations in human cancers, have been described in several types of haemato logic malignancies.4 By contrast, only a few studies have focused on p53 abnormalities in various categories of T-cell lymphomas and to the best of our knowledge, parasoriasis has not been studied so far.5–10 Studies of p53 protein expression in primary cutaneous T-cell lymphoma have shown to be increased in the late stages of the dis ease. This prompted us to investigate the incidence of p53 gene mutations in parapsoriasis and its role in the pathogenesis.Publication Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema(Elsevier, 2021-05-21) Can, Pelin Kuteyla; Değirmentepe, Ece Nur; Etikan, Pırıl; Kızıltaç, Kübra; Gelincik, Aslı; Demir, Semra; Büyüköztürk, Suna; Haşal, Eda; Başkan, Emel Bülbül; Aydın, Ömur; Maurer, Marcus; Weller, Karsten; Kocatürk, Emek; Haşal, Eda; BÜLBÜL BAŞKAN, EMEL; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; 0000-0001-6310-5107; FZP-3964-2022 ; CEB-8268-2022Objective: Recurrent Angioedema (RAE) is characterized by sudden swelling of mucosal surfaces or deep dermis and is either mast cell-(MMAE) or bradykinin-mediated (BMAE). How patients with BMAE and MMAE differ in terms of disease activity and impact remains largely unknown. Here, we determined validity, reliability, and sensitivity to change of Turkish versions of angioedema activity score (AAS) and quality of life questionnaire (AE-QoL) and used both instruments to investigate and compare patients with BMAE and MMAE. Methods: Turkish versions of AAS28 and AE-QoL were applied to 94 patients with RAE (18-72 years). Patients' global self-assessment of QoL (PGA-QoL), disease activity (PGA-DA-VRS, PatGA-DA-VAS), and 12-Item-Short Form Survey were used at week 4 (visit 2), and week 8 (visit 3). De-mographic characteristics, clinical features, and AAS28 and AE-QoL values were compared be-tween 31 patients with BMAE and 63 patients with MMAE. Results: Turkish AAS28 and AE-QoL showed excellent internal consistency, high reproducibility and known-groups validity. Compared to patients with MMAE, BMAE patients were younger (34.6 +/- 10.7 vs. 40.7 +/- 13.3 years), had longer disease duration (236 +/- 178 vs. 51 +/- 78 months), high prevalence of family history (63% vs 14%), longer duration of attacks (65 +/- 20 vs. 40 +/- 25 h), and they were more commonly affected by upper airway angioedema (70% vs 23%). Disease activity (AAS28) was lower (29.3 +/- 24.6 vs 55.2 +/- 52.9), but AE-QoL was higher (44.2 +/- 16.1 vs 34.5 +/- 22.5) in BMAE patients as compared to MMAE patients. Conclusions: Patients with BMAE and MMAE have distinct disease characteristics. Recurrent bradykinin-mediated angioedema impacts quality of life more than mast cell-mediated angioe-dema. The discriminating characteristics of patients with BMAE and MMAE may help to improve the diagnosis and management of patients with RAE.Item Atopik dermatit tedavisi(Uludağ Üniversitesi, 2004) Tunalı, Şükran; Başkan, Emel Bülbül; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.Item Bazal hücreli karsinomda tek başına veya intralezyonel interferon ile birlikte imikimod kullanımı ile klinik başarı(Deri Zührevi Hastalıklar Derneği, 2013-12) Sarıcaoğlu, Hayriye; Algan, Sema Ipek; Turan, Ayşegül; Başkan, Emel Bülbül; Turan, Hakan; Adım, Şaduman Balaban; Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6603722836; 55791672200; 14055302400; 6602518817; 16835681500; 15730076300Bazal hücreli karsinom (BHK), insanlarda en sık görülen deri kanseri tipidir. BHK'ların tedavisinde cerrahi, halen altın standart olarak yerini korumaktadır. Buna rağmen, cerrahiye uygun olmayan ve kozmetik kaygıları olan bireylerde imikimod krem ve intralezyonel interferon (IFN) alfa2b gibi, daha az invaziv, cerrahi olmayan seçenekler de bulunmaktadır. Yalnız başına imikimod ya da imikimod ile kombine olarak interferon alfa-2b ile başarılı bir şekilde tedavi ettiğimiz değişik alt tiplerde 11 BHK vakasını sunduk. 2005-2010 yılları arasında polikliniğimizde histopatolojik olarak BHK oldukları kanıtlanmış, tek başına ya da IFN alfa-2b ile kombine olarak imikimod ile tedavi edilmiş çeşitli alt tiplerdeki hastalar bu rapora dahil edildi. Sunduğumuz 11 hastadan sadece 4 'ü (3 infiltratif, 1 solid tipler) topikal imikimoda ek olarak haftada 3 gün intralezyonel interferon alfa2b 3 milyon IU tedavisi de almıştı. Geri kalan 7 hasta sadece imikimod %5 krem kullanmıştı. Tüm hastalarda bu tedavi seçenekleri ile tam iyileşme sağlandığı görüldü. Bu olgulardaki gözlemlerimiz, İmikimodun sadece yüzeyel değil; infiltratif, solid, nodüler tip BHK'larda da etkili olduğunu düşündürmektedir. İmikimod, sadece yüzeyel değil, aynı zamanda, infiltratif, solid ve nodüler tip BHK'larda da etkili olduğunu düşündürmektedir. İntralezyonel interferon alfa-2b'nin de BHK'larda etkili olduğu ve imikimod ile kombine edildiğinde sinerjistik etki gösterdiği bilinmektedir.Item Benign neonatal hemangiomatosis with conjunctival involvement - Report of a case and review of the literature(Acta Dermato-Venereologica, 2002) Başkan, Emel Bülbül; Sarıcaoğlu, Hayriye; Baykara, Mehmet; Tunalı, Şükran; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabiilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Oftalmoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6602518817; 23093006700; 6603722836; 7004191748Hemangiomas are the most common tumours of infancy. When limited to the skin, multiple lesions have a benign course and excellent prognosis but in cases of visceral involvement, the morbidity and mortality rates are high. We report a rare case of a female infant with benign neonatal hemangiomatosis who had dramatic conjunctival involvement. The spectrum of neonatal hemangiomatosis is reviewed, highlighting the importance of differentiation of the two extremes of this disorder.Item Biologic agents in psoriasis(Vakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği, 2008-12) Başkan, Emel Bülbül; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6602518817Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.Publication Biosimilars(Galenos Yayıncılık, 2022-01-01) Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim DalıFor a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.Item A case of epidermodysplasia verruciformis associated with squamous cell carcinoma and Bowen's disease: A therapeutic challenge(Taylor & Francis, 2006) Başkan, Emel Bülbül; Tunalı, Şükran; Adım, Saduman Balaban; Turan, Ayşegül; Toker, Semra; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6602518817; 7004191748; 15730076300; 14055302400; 14054750900Epidermodysplasia verruciformis (EV) is a very rare and chronic disease characterized by a susceptibility to cutaneous infections by a group of phylogenetically related human papillomavirus (HPV) types. We present here a 52-year-old man previously diagnosed and treated as squamous cell carcinoma but also found to have epidermodysplasia verruciformis lesions in association with Bowen's disease. The patient was effectively treated with a combination of interferon therapy (6 million units, twice a week) and topical imiquimod for Bowen's disease (five times a week). We conclude that topical imiquimod is very effective in the treatment of Bowen's disease and may be combined with systemic interferon therapy in rare cases with multiple vivid presentations of HPV infections.Item A case of generalized granuloma annulare with myelodysplastic syndrome: Successful treatment with systemic isotretinoin and topical pimecrolimus 1% cream combination(Wiley, 2007-05) Başkan, Emel Bülbül; Turan, Ayşegül; Tunalı, Şükran; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; 0000-0002-0144-3263; 6602518817; 14055302400; 7004191748Item A case of granuloma annulare in a child following tetanus and diphtheria toxoid vaccination(Wiley, 2005-09) Başkan, Emel Bülbül; Tunalı, Şükran; Kaçar, Seval Doǧruk; Adım, Şaduman Balaban; Sarıcaoğlu, Hayriye; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6602518817; 7004191748; 55394051200; 15730076300; 9739878100Item A case of Merkel cell carcinoma and review of the literature(Wiley, 2017-06) Yazıcı, Serkan; Başkan, Emel Bülbül; Adım, S. B.; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; JDD-8680-2023; AAH-1388-2021; AAH-2459-2021Item A case of syringocystadenoma papilliferum: An unusal localization on postoperative scar(Wiley, 2002-10-02) Sarıcaoğlu, Hayriye; Başkan, Emel Bülbül; Özuysal, Sema; Tunalı, Şükran; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabiilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; 6603722836; 6602518817; 56616314600; 7004191748Item Chandrakala SFCR The value of spectrophotometric intracutaneous analysis in the noninvasive diagnosis of nonmelanoma skin cancers(Wiley, 2013-06-18) Hacıoǧlu, Şenay; Sarıcaoğlu, Hayriye; Başkan, Emel Bülbül; Uner, S. I.; Aydoĝan, Kenan; Tunalı, Şükran; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; 0000-0002-0193-1128; AAH-6216-2021; 36196495300; 6603722836; 6602518817; 55914302400; 9739755800; 7004191748Background. Spectrophotometric intracutaneous analysis (SIAscopy) is a recently introduced, noninvasive, rapid and practical method for monitoring pigmented lesions, which calculates the amount of collagen, melanin and haemoglobin deep in the papillary dermis. Aim. To evaluate the value of SIAscopy in the diagnosis of nonmelanoma skin cancers (NMSC). Methods. In total, 80 lesions of 76 patients were clinically evaluated by the first investigator, and the data recorded. Eight months after the clinical evaluation, all lesions were evaluated again by the same investigator, using images (SIAgraphs) obtained by the SIAscope. All SIAgraphs were also evaluated by a second investigator, and all dermatoscopic images by a third, independently of each other. All diagnoses were compared with histopathological diagnoses. Results. The clinical diagnosis was calculated to have a sensitivity of 79% and specificity of 84%. The SIAscopic diagnoses of the first and second investigators had a sensitivity of 55% and 93%, and a specificity of 88% and 53%, respectively, while the dermatoscopic diagnoses of the third investigator had a sensitivity of 86% and specificity of 80%. There was no statistical accordance between the first and second investigators according to the accuracy of SIAscopic diagnoses (P<0.01). The area under the curve for the receiver operator characteristic was 0.82 for clinical diagnosis, 0.73 and 0.80 for the SIAscopic evaluation of the first and the second investigators, respectively, and 0.87 for the dermatoscopic evaluation of the third investigator. Conclusions. Our findings show that dermatoscopic findings are more valuable than SIAscopic and clinical findings for the noninvasive diagnosis of NMSC. We consider that SIAscopy makes no substantial contribution towards the differential diagnosis of NMSC.Item Characteristics and risk profile of patients with psoriasis included in the Turkish national registry PSR-TR(Wiley, 2017-10) Onsun, Nahide; Dizman, Didem; Özkaya, Dilek Bıyık; Erkılıç, A. C.; Özarmağan, G.; Gürer, M. A.; Başkan, Emel Bülbül; Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021Publication Clinical and demographical characteristics of familial Behcet's disease (southeast Marmara region)(Karger, 2019-01-01) Kalın, Zübeyde Ceylan; Sarıcaoğlu, Hayriye; Yazıcı, Serkan; Aydoğan, Kenan; Başkan, Emel Bülbül; SARICAOĞLU, HAYRİYE; YAZİCİ, SERKAN; AYDOĞAN, KENAN; BÜLBÜL BAŞKAN, EMEL; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-2459-2021; AAH-6216-2021; AAH-1388-2021; DQE-8993-2022Background: Familial aggregation in Behcet's disease (BD) has been reported in Turkish and Japanese populations. While the frequency of familial cases has been reported to be 2-5% worldwide, this rate reaches up to 15% in the Middle East. Objective: This study aimed to determine the incidence of familial BD cases followed in the BD polyclinic and to compare their clinical and demographic characteristics to those observed in sporadic cases. Methods: Data related to BD patients who were followed between 1995 and 2014 were collected from computerized archive records and were assessed for detailed family histories. Only first-degree relatives (brother, sister, mother, father, children) were considered to be cases of familial BD. Clinical and demographic features were retrieved. Our BD polyclinic is located in the Southeast Marmara Region in Turkey. Results: BD was detected in 36 first-degree relatives of 33 patients out of 840 patients with BD. A total of 45 patients were diagnosed as familial BD; 23 were female, and 22 were male. In our patients, the incidence of familial BD was determined to be 3.9%. The rates for HLA-B5 positivity, ocular involvement, genital ulcers, and erythema nodosum were determined to be 86.6% (26/30), 26.6%, 82.2%, and 60%, respectively. None of the patients had neurological involvement, but 2 had vascular involvement. Conclusion: This study may contribute to the epidemiological data of BD from Turkey. (C) 2019 S. Karger AG, BaselItem Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis(Taylor & Francis, 2015-10-24) Başkan, Emel Bülbül; Yazıcı, Serkan; Tunalı, Sükran; Sarıcaoğlu, Hayriye; Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; AAH-2459-2021; 6602518817; 25925620000; 7004191748; 6603722836Background: Severe forms of psoriasis including erythrodermic or pustular psoriasis, which require a more aggressive therapeutic approach such as phototherapy or systemic therapies, are rarely seen. Systemic toxicity and long-term safety of these agents are serious concerns in children. Objective: We report our experience on the efficacy and safety of cyclosporine A treatment in 22 patients of childhood psoriasis. Methods: We retrospectively analyzed the records of all patients less than 18 years of age treated with systemic cyclosporine A therapy at our clinic between January 2000 and March 2009. Demographic features as well as other relevant data including previous therapies, the dosage and duration of cyclosporine A therapy, response to treatment and side effects were retrieved from the patients' records. Results: A total of 22 children were treated with systemic cyclosporine A therapy. Seventeen patients were found to be excellent responders. The mean therapeutic dosage of cyclosporine A was 3.47 +/- 0.62 mg/kg/day. The mean duration of cyclosporine A therapy was 5.68 +/- 3.29 months. The median time to total clearance of the lesions was 4.0 weeks. Conclusion: We conclude that cyclosporine A therapy is equally effective and safe in pediatric psoriasis patients as in adults.Item Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis(Wiley, 2010-07) Başkan, Emel Bülbül; Yazıcı, Serkan; Tunalı, Şükran; Sarıcaoğlu, Hayriye; Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı.; 0000-0002-0144-3263; AAH-1388-2021; AAH-2459-2021; 6602518817; 25925620000; 7004191748; 6603722836Severe forms of psoriasis including erythrodermic or pustular psoriasis, which require a more aggressive therapeutic approach such as phototherapy or systemic therapies, are rarely seen. Systemic toxicity and long-term safety of these agents are serious concerns in children. Objective: We report our experience on the efficacy and safety of cyclosporine A treatment in 22 patients of childhood psoriasis. Methods: We retrospectively analyzed the records of all patients less than 18 years of age treated with systemic cyclosporine A therapy at our clinic between January 2000 and March 2009. Demographic features as well as other relevant data including previous therapies, the dosage and duration of cyclosporine A therapy, response to treatment and side effects were retrieved from the patients’ records. Results: A total of 22 children were treated with systemic cyclosporine A therapy. Seventeen patients were found to be excellent responders. The mean therapeutic dosage of cyclosporine A was 3.47 ± 0.62 mg/kg/day. The mean duration of cyclosporine A therapy was 5.68 ± 3.29 months. The median time to total clearance of the lesions was 4.0 weeks. Conclusion: We conclude that cyclosporine A therapy is equally effective and safe in pediatric psoriasis patients as in adults.